Electronic Components

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

AmpliTech Group Reports Q2 Revenue of About $11 Million

Amesite

Meiwu Tech

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

NextNRG

AMPGR

AMPGW

AMPG

AMPGZ

AmpliTech Group (NASDAQ:AMPG) reported quarterly earnings of ($0.14) per share, missing estimates by $0.07. The company generated $4.48 million in revenue, exceeding expectations of $4.30 million. It has a negative net margin of 33.77% and a negative return on equity of 21.04%. The stock traded down 3.3% to $2.65, with a market cap of $60.82 million. Analysts have a consensus "Sell" rating on the stock, with hedge funds owning 10.99% of shares. AmpliTech specializes in RF and microwave components for defense and aerospace applications.

Market Beat

ISHRS Aero & Def

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AmpliTech

Invesco Aero & Defense ETF

SPDR S&P Aerospace & Def

AmpliTech Group (NASDAQ:AMPG) Releases Earnings Results, Misses Estimates By $0.07 EPS

AmpliTech Group, Inc. (AMPG) has announced the approval of its Series A and B Rights listing on the Nasdaq Capital Market, set to begin trading on February 3, 2026, under the symbols "AMPGR" and "AMPGZ". The Series A Rights have a subscription price of $5 per share, with a deadline for subscription certificates by July 18, 2026. The Series B Rights are priced at $6 per share, with a deadline of November 20, 2026. AmpliTech specializes in RF microwave components and 5G network solutions, serving various global markets.

fidelity

AmpliTech Group Lists Series A & B Rights on Nasdaq

SBIO

DNLI

Devonian Health Group Inc. has appointed Dennis Turpin as Chief Financial Officer, effective immediately. Turpin, a seasoned executive with over 25 years in the biopharmaceutical industry, will also remain on the Board of Directors. He replaces Viktoria Krasteva, who will assist in the transition until February 2026. Additionally, 25,000 stock options were granted to Turpin, with an exercise price of $11.50. The company corrected previous stock option grants, adjusting the exercise price from $0.18 to $0.19, and post-consolidation options now reflect a price of $11.40.

StockTitan

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Denali Therap

Invesco Biotechnology & Genome ETF

DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT | DVHGF Stock News

CLFD

Clear Street Group Inc. has filed a registration statement on Form S-1 with the U.S. SEC for a proposed initial public offering of its Class A common stock. The company plans to list on the Nasdaq Global Select Market under the ticker symbol "CSIG." The number of shares and price range for the IPO are yet to be determined, and the offering is subject to market conditions.

rttnews

Clearfield

Clear Street Group Files For IPO, Plans Nasdaq Listing Under Symbol 'CSIG'

Earnings Watch

AMPLITECH GROUP INC. C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 6.094 M

AMPLITECH GROUP INC. C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 11.03 M

AMPLITECH GROUP INC. C/WTS 26/02/2026(TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 11 M

AMPLITECH GROUP INC. C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 3.599 M

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)(AMPGW.US)